Ethical challenges in the clinical translation of anti-amyloid monoclonal antibodies for Alzheimer’s disease: a scoping review
BackgroundThe development and evaluation of anti-amyloid beta monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease have been accompanied by extensive ethical debate spanning clinical trials, regulatory processes, prescribing practices, and healthcare delivery. This scoping review examined literature published between 2006 and 2026 to identify and clarify the landscape of ethical…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
What We Give Up
United States
-
120 Funny Quotes From Famous People: Hilarious Humor by Celebrities
Sweden
-
18 Habits that Often Make Our Lives 98 Percent Harder
United States
-
Editorial: Sensory processing in autism: mechanisms, impacts and interventions
Switzerland
-
Understanding non-psychiatric nurses’ experiences of caring for patients with mental-physical comorbidity: a descriptive phenomenological study
Switzerland
-
Incidence and risk factors for enteral nutrition intolerance in psychiatric patients with comorbid medical conditions: a retrospective cohort study
Switzerland
-
Reduced contagious yawning in psychiatric disorders: a systematic review of potential social-cognitive mechanisms
Switzerland
-
Benzodiazepine prescribing in chronic military-related PTSD: real-world patterns and correlates in specialized care
Switzerland